Lixte Biotechnology, Inc. - LIXT Company Short-Term Debt

Lixte Biotechnology, Inc. (LIXT) - corporate logo

The lack of stable cash flow due to the clinical status of its developments makes Lixte Biotechnology (LIXT) dependent on external funding. Current short-term liabilities displayed on the GURU.Markets platform confirm this hypothesis, with the latest value recorded as 0.00. The business relies on licensing inhibitor formulas to third-party behemoths, while scalability is driven by global sales of patented drugs with minimal production costs.

LIXT (Lixte Biotechnology Holdings, Inc.) Company Short-Term Debts history from 07/04/2022 to 07/06/2026

Lixte Biotechnology, Inc. - analytical breakdowns and key metrics (LIXT)

- price and consensus price forecast:
Stock Price Lixte Biotechnology Holdings, Inc.|LIXT - Average Forecast Price
- market capitalization data:
Market Value Lixte Biotechnology Holdings, Inc.|LIXT - Value Adjusted for Debt and Cash
- book capitalization data:
Book Value per Share Lixte Biotechnology|LIXT - Book Capitalization|Market Value to Book Value Ratio lixte.com|LIXT - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Lixte Biotechnology|LIXT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lixte Biotechnology|LIXT - Company Cumulative Debt|Debt to Book Capitalization Ratio Lixte Biotechnology Holdings, Inc.|LIXT - Company Long-Term Indebtedness|Company Short-Term Debts Lixte Biotechnology
Fundamental company valuation:Lixte Biotechnology
Signature product of Lixte Biotechnology

Geopolitical tensions and sanctions are complicating the logistics of reagents for Lixte Biotechnology (LIXT) oncology research, directly impacting operating expenses. The short-term debt time series captures obligations of up to one year; a decrease in this metric could signal either a post-crisis balance sheet recovery or a loss of access to credit, which is critical if drug development timelines are extended.

Competitors of Lixte Biotechnology (LIXT)

INCY (Incyte) - Company Short-Term Debts|HCM: Short-Term Debt|Company Short-Term Debt Nuvation Pharma NUVB|Day One Biopharmaceuticals Inc (DAWN) - Company Short-Term Loans and Borrowings|MNPR (Monopar Therapeutics) - Company Short-Term Debts|Company Short-Term Debts INBX|Company Short-Term Debt I-Mab (IMAB)|Company Short-Term Debt Fennec Pharma FENC|Company Current Liabilities Heron Therapeutics, Inc.|Nuvectis Pharma, Inc - Company Short-Term Loans and Borrowings|CHRS (Coherus BioSciences, Inc.) - Company Short-Term Debt|CRBP: Short-Term Debt|Company Short-Term Debt cardiffoncology.com|BeyondSpring, Inc. (BYSI) - Company Short-Term Indebtedness|Company Short-Term Debts BCAB|Company Current Liabilities CTXR|Cellectar Biosciences - Company Short-Term Debt|Short-Term Debt BLRX (biolinerx.com)|Company Short-Term Debt Can-Fite BioPharma Ltd. CANF|Aprea Therapeutics Inc. - Company Short-Term Debt|KZIA (Kazia) - Company Short-Term Debt|SLXN - Short-Term Debt|Company Short-Term Debts NCNA (nucana.com)|Short-Term Indebtedness chimerix.com|Company Current Liabilities CYCC (Cyclacel)|Short-Term Debt G1 Pharma (GTHX)|Kronos Bio Corp (KRON) - Company Current Liabilities|Company Short-Term Loans and Borrowings Kintara Pharma KTRA|Company Current Liabilities Oncternal Therapeutics (ONCT)|Amount of Current Liabilities portagebiotech.com PRTG